Achieving 90-90-90 Targets: Integrating TB and HIV Testing
No invitations necessary; open to all conference registrants
Wednesday, 7 December
CTICC room location: 1.4
Medical technicians/scientists, policy makers and donors
On the 7th of June 2016, the heads of states and governments made a historic commitment to end the TB and AIDS epidemic by 2030. Dr Aaron Motsoaledi, Chair of the Stop TB Partnership Coordinating Board and Minister of Health of South Africa, stated, “For the first time, we are united and determined to see this fight through to the end. This UN High-Level Meeting on Ending AIDS comes at a turning point for both the HIV and the TB communities, as we set our aim on ending the scourges of these twin diseases by 2030” 1.
In June 2016, the WHO prequalified Xpert® HIV-1 Qual. Prequalification of Xpert® HIV-1 Viral Load is eminent. For the first time, the global health community will have a polyvalent platform with TB and HIV (qualitative and quantitative) testing capabilities which marks a turning point for both the HIV and the TB communities to end the epidemics.
The availability of polyvalent near point of care and point of care diagnostics platforms with TB and HIV (qualitative and quantitative) testing capabilities provides the opportunity to integrate TB and HIV diagnostic programs starting at the health clinic level. The symposium will focus on identifying challenges and opportunities for integrating TB and HIV programs in resource limited settings. It will also provide research-based evidence to demonstrate the value of using the GeneXpert® polyvalent systems in integrating TB and HIV programs. The panel discussion will engage policy makers and donors towards creating an enabling environment for TB and HIV integration and meeting the 90-90-90 goals for both diseases by 2030.
SESSION LEARNING OBJECTIVES:
Increased understanding of:
- The performance of HIV and TB assays on the GeneXpert®,
- Key challenges and opportunities for TB and HIV integration in resource limited settings
- and, HIV and TB integration best practices which can be leveraged by countries
Mr. Philippe Jacon, Cepheid, France
Philippe Jacon joined Cepheid in January 2013. In his role of President, Emerging Markets, he leads the company’s development in developing and emerging countries, including the HBDC (High Burden and Developing Countries) program which aims at giving access to a number of state-of-the-art molecular diagnostic tests (Xpert®MTB/Rif, Xpert®HIV-1 VL, Xpert® HIV Qual, Xpert® HCV, Xpert® HPV, etc.) to the populations in need, at concessional prices. Prior to Cepheid, Philippe Jacon held the position of CEO of the Foundation for Innovative New Diagnostics (FIND) since October 2011.
Dr. Jilian A. Sacks, Clinton Health Access Initiative, USA
Jilian A. Sacks is a Scientist on the Global Lab Services Team at the Clinton Health Access Initiative (CHAI), where she serves as a technical advisor for CHAI’s HIV and Hepatitis programs, working to expand access to affordable, appropriate and accurate diagnostic testing in resource-limited settings. Prior, Dr. Sacks was an Earth Institute Postdoctoral Fellow at Columbia University (New York, NY) for 2 years, where she performed implementation research on novel point-of-care and mobile health technologies to strengthen HIV, TB, maternal and child health, and Ebola programs in rural sites throughout Sub-Saharan Africa in association with the Millennium Villages Project.
Prof. Lesley Scott, National Health Laboratory Services, South Africa
Prof Scott is an applied research and development scientist in the department of molecular medicine and haemataology at the University of the Witwatersrand in Johannesburg, South Africa’s, and head of R&D for the National Priority Program focusing on designing, developing, evaluating and implementing laboratory quality diagnostics for HIV/TB. Her experience extends from high throughput to point of care (POC) technologies.
Dr. Trevor Peter, Clinton Health Access Initiative, Botswana
Dr. Trevor Peter is the Senior Scientific Director, Diagnostics at the Clinton Health Access Initiative where he has worked since 2005. He is also the Chair of the African Society for Laboratory Medicine. Dr. Peter has over 20 years experience in the fields of diagnostics, infectious diseases research and public health. He has supported the scale-up of national HIV testing programs across over 30 countries in Africa, Asia, Eastern Europe, the Caribbean and South America. Previously, Dr. Peter headed the Botswana HIV Reference Laboratory under the Botswana-Harvard School of Public Health Partnership and was involved in infectious disease epidemiology research.